Lack of synergy between ADX40 and GM-CSF. (A) Groups of mice requiring GM-CSF injections were immunized on days −28, −27, −26, −25, −13, −12, −11, and −10. (B) Anti-Id–specific titer after boost (day −1) was significantly increased in ADX40-A20 ± GM-CSF groups compared with the PBS and KLH-A20 + GM-CSF groups (mean ± SD; n = 20). *P < .05; *** P < .0005. (C-D) Kaplan-Meier survival curve shows significantly increased median survival of mice (C) and lower tumor burden (D) of all treatment groups compared with PBS (n = 20). ***P < .0001.